BindingSite_syringe.jpg

Binding Site

Clinical Laboratory Diagnostics

Founded by researchers at the University of Birmingham, Binding Site has continued to research, develop, manufacture and distribute specialist immunodiagnostic assays and instrumentation for over 30 years.

Company Background

Significant room for continued market penetration of core products

Strong R&D culture and attractive product pipeline

Academic origins with research focus

Vision & Outlook

Support expansion and investment in jobs and new technology allowing to bring Binding Site's life changing diagnostics to more patients around the world while focusing on ethical, social, environmental, cultural and economic dimensions in all aspects of its business

Grow the existing products through increased market penetration, especially for the main product Freelite

Highlights & Updates

Joined forces with Birmingham University and launched tests to detect COVID-19 antibodies in the beginning of the pandemic

binding_site_logo.png

SECTOR

Healthcare

REVENUES 2021

EUR 190 million

EMPLOYEES

1,110

OWNERSHIP

Fund VII, CV1

HEAD OFFICE

UK

INVESTMENT DATE

2011

MANAGEMENT

Stefan Wolf

CEO

Mark Culwick

CFO

CHAIRPERSON

Mark Stevenson

RESPONSIBLE ADVISOR

Jonas Agnblad

Partner | Co-Head of Healthcare